Abstract:Background The concept of Mixed Connective Tissue Disease (MCTD) was first proposed by Sharp and his colleagues in 1972.1 MCTD has overlapping features between at least two autoimmune diseases, such as SLE, SSc, PM/DM and RA. Regulatory T cells (Treg cells) play a critical role in the maintenance of immune tolerance and the regulation of immune responses. Treg cell dysfunction contributes to the initiation of pathogenesis and the maintenance of high disease activity in RA and SLE.2 Recently, some studies have indicated that the proportion of Treg cells was different from healthy controls in SSc patients.3 Therefore, MCTD may be associated with Treg cells. Objectives To explore the status of CD4+T cells in peripheral blood of patients with MCTD; to explore the effect of low dose interleukin -2 (IL-2) treatment on the balance of Treg cells and Th17 cells in patients with MCTD, and to observe the short-term curative effect. Methods CD4+T cells in the peripheral blood of 58 MCTD patients and 33 healthy controls were analyzed by flow cytometry. All of 58 cases were treated with standard therapy, including corticosteroids, NSAIDs, immunosuppressants, or combination therapy. Among them, 26 cases of MCTD without using immunosuppressant (CYC, MTX, LEF, MMF), were as untreated group, another 32 cases were as treated group. Then we compared the difference of CD4+T cells between two groups. In 58 patients with MCTD, a total of 27 patients were treated with low-dose IL-2 (50WIU) on the basis of standard treatment for 5 days. The difference of CD4+T cells before and after treatment with IL-2 was compared. Results The absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD was significantly lower than those in healthy controls. There was no significant difference in the absolute count of CD4+CD25+FOXP3+Treg cells in the peripheral blood between the treated group and the untreated group. The absolute count of CD4+CD25+FOXP3+Treg cells was significantly higher than those before treatment with IL-2. Conclusions The absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD were significantly reduced, which may be the mechanism of immune imbalance in MCTD patients. The decrease of the absolute count of CD4+CD25+FOXP3+Treg cells in peripheral blood of patients with MCTD was not associated with the use of immunosuppressive agents. Low dose and short-term IL-2 treatment may increase the absolute count of CD4+CD25+FOXP3+Treg cells in the peripheral blood in patients with MCTD, so as to restore the immune balance in patients with MCTD. References Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specifi c antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148–159. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol, 2009, 16(4):274–279. Cordiali-Fei P, Mussi A, D9Agosto G, et al. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol, 2013, 2013:390563. Acknowledgements Thanks to my supervisor, my colleagues and superiors. Disclosure of Interest None declared

Efficacy of low-dose intravenous cyclophosphamide in combination with immunoclearance in treatment of systemic lupus erythematosus

Comparison of Short Interval and Low Dose (SILD) with High Dose of Cyclophosphamide in the Susceptibility to Infection in SLE: a Multicentrereal-World Study

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study

[A Multicenter Study on the Tolerance of Intravenous Low-Dose Cyclophosphamide in Systemic Lupus Erythematosus].

Preliminary study of nonmyeloablative cyclophosphamide pulse treatment for patients with refractory lupus nephritis

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Low Dosage Use of Cyclophosphamide Improves the Survival of Patients with Systemic Lupus Erythematosus.

The Effect of Cyclophosphamide Treatment on the Prognosis of Patients with Systemic Lupus Erythematosus

Efficacy of low-dose leflunomide in lupus nephritis: A multi-center prospective study

Leflunomide Versus Cyclophosphamide in the Induction Treatment of Proliferative Lupus Nephritis in Chinese Patients: a Randomized Trial.

Cyclosporine A in Treatment of Membranous Lupus Nephropathy

Randomized Controlled Trial of Tacrolimus Versus Intravenous Cyclophosphamide in the Induction Therapy of Class Ⅴ Plus Ⅳ Lupus Nephritis

AB0612 Efficacy of Low Dose and Short-Term IL-2 Treatment to Expand Endogenous Regulatory T Cells in Patients with Mixed Connective Tissue Disease

A Prospective Clinical Trail of Corticosteroids in Combination with Mycophenolate Mofetil Dispersible Tablets and Tacrolimus for the Induction Treatment of Lupus Nephritis

Efficacy and safety of oral versus intravenous cyclophosphamide in treatment of connective tissue disease‐related interstitial lung disease

Tacrolimus versus intravenous cyclophosphamide in the induction therapy of diffuse proliferative lupus nephritis

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus

AB0525 Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide for Class Ⅳ Plus Ⅴ Lupus Nephritis

[Efficacy and Safety of Low-Dose Rituximab Combined with Different Dosage of Glucocorticoids for Immune Thrombocytopenia].